Panitumumab a novel drug in cancer treatment.
作者： G. Cartenì , R. Fiorentino , L. Vecchione , B. Chiurazzi , C. Battista
关键词:
摘要: The epidermal growth factor receptor (EGFR) is a member of the erbB family overexpressed in most solid tumors. In cancer cells, overexpression EGFR correlates with development and progression tumor. Panitumumab fully human monoclonal antibody that blocks extracellular domain has not been associated formation any antibodies directed against it. This review summarizes on preclinical clinical panitumumab As bevacizumab cetuximab have approved for colorectal because their improvements progression-free survival overall when chemotherapy, represents an interesting molecule which needs more phase III studies to validate its efficacy.
paperity.org
oxfordjournals.org
elsevier.com参考文章(34)
C. Geoffrey Davis, Michael L. Gallo, Jose R.F. Corvalan, Transgenic mice as a source of fully human antibodies for the treatment of cancer. Cancer and Metastasis Reviews. ,vol. 18, pp. 421- 425 ,(1999) , 10.1023/A:1006321231510
X.-D. Yang, A. Jakobovits, Ping Wang, C. G. Davis, X.-C. Jia, J. R. F. Corvalan, Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Research. ,vol. 59, pp. 1236- 1243 ,(1999)
Timothy S. Lewis, Paul S. Shapiro, Natalie G. Ahn, Signal Transduction through MAP Kinase Cascades Advances in Cancer Research. ,vol. 74, pp. 49- 139 ,(1998) , 10.1016/S0065-230X(08)60765-4
Zhen Fan, Hideo Masui, John Mendelsohn, Jose Baselga, Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus cis-Diamminedichloroplatinum on Well Established A431 Cell Xenografts Cancer Research. ,vol. 53, pp. 4637- 4642 ,(1993)
J. Baselga, D. Pfister, M.R. Cooper, R. Cohen, B. Burtness, M. Bos, G. D’Andrea, A. Seidman, L. Norton, K. Gunnett, J. Falcey, V. Anderson, H. Waksal, J. Mendelsohn, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin Journal of Clinical Oncology. ,vol. 18, pp. 904- 914 ,(2000) , 10.1200/JCO.2000.18.4.904
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
Lutz Riechmann, Michael Clark, Herman Waldmann, Greg Winter, Reshaping human antibodies for therapy. Nature. ,vol. 332, pp. 323- 327 ,(1988) , 10.1038/332323A0
Fairooz Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher, Neal J. Meropol, William F. Novotny, Grazyna Lieberman, Susan Griffing, Emily Bergsland, Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 21, pp. 60- 65 ,(2003) , 10.1200/JCO.2003.10.066
Kenneth A Foon, Xiao-Dong Yang, Louis M Weiner, Arie S Belldegrun, Robert A Figlin, Jeffrey Crawford, Eric K Rowinsky, Janice P Dutcher, Nicholas J Vogelzang, Jared Gollub, John A Thompson, Garry Schwartz, Ronald M Bukowski, Lorin K Roskos, Gisela M Schwab, Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody International Journal of Radiation Oncology Biology Physics. ,vol. 58, pp. 984- 990 ,(2004) , 10.1016/J.IJROBP.2003.09.098
Naureen Starling, David Cunningham, Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. Current Opinion in Oncology. ,vol. 16, pp. 385- 390 ,(2004) , 10.1097/01.CCO.0000128278.15371.E4